Skip to main content

A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects with, or at Risk for, Manifest Huntington's Disease

Clinical Trial Grant
Duke Scholars

Administered By

Neurology, Movement Disorders

Awarded By

Annexon Biosciences

Start Date

August 6, 2020

End Date

December 31, 2022
 

Administered By

Neurology, Movement Disorders

Awarded By

Annexon Biosciences

Start Date

August 6, 2020

End Date

December 31, 2022